维普期刊资源整合服务平台（V6.5）

85篇 您的检索式：作者名="RIELY G J"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Clinical definition of ac-quired resistance to epidermal growth factor receptor tyrosine ki-nase inhibitors in non-small-cell lung cancer显示文摘	Jackman D Pao W Riely G J		0，，2：	1
2	Initial phase II resultswith Crizotinib in advanced ALK-positive non-small celllung cancer(NSCLC):PROFILE 1005 显示文摘	Crino L Kim Ds Riely G J	2011	J Clin Oncol2011，29，15：	1
3	Lung adenocarcinoma:modifica-tion of the 2004 WHO mixed subtype to include the major histologicsubtype suggests correlations between papillary and micropapillary ade-nocarcinoma subtypes,EGFR mutations and gene expression analysis显示文摘	Motoi N Szoke J Riely G J	2008	Am J Surg Pathol2008，32，6：	1
4	KRAS mutations in non-small cell lung cancer 显示文摘	Riely G J Marks J Pao W	2009	Proc Am Thorac Soc2009，6，2：	1
5	Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases 显示文摘	Yoshizawa A Motoi N Riely G J	2011	Mod Pathol2011，24，5：	1
6	Impact of pro- posed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases显示文摘	YOSHIZAWA A MOTOI N RIELY G J	2011	Mod Pathol2011，24，5：	1
7	Frequency and distinc- tive spectrum of KRAS mutations in never smokers, with lung ade- nocarcinoma显示文摘	Riely G J Kris M G Rosenbanm D	2008	Clin Cancer Res2008，14，18：	1
8	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials 显示文摘	Travis W D Brambilla E Riely G J	2013	J Clin Oncol2013，31，8：	1
9	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon I9 and 21 mutations treated with gefitinib or er显示文摘	Riely G J Pao W Pham D	2006	Clin Cancer Res2006，12，：	1
10	Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer显示文摘	Rizvi N A Riely G J Azzoli C G	2008	J Clin Oncol2008，26，4：	1
11	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials显示文摘	Travis W D Brambilla E Riely G J	2013	J Clin Oncol2013，31，8：	1
12	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinih fol- lowed by the addition of everolimus 显示文摘	Riely G J Kris MG Zhao B et o2	2007	Clin Cancer Res2007，13，：	1
13	Beyond 'second-line' in non-small cell lung cancer: therapy and supportive care 显示文摘	Martins R G Reynolds C H Riely G J	2015	Am Soc Clin Oncol Educ Book2015，，：	1
14	Initial phase II re- sults with crizotinib in advanced ALK-positive non- small cell lung cancer (NSCLC): PROFILE 1005显示文摘	Crino L Kim D Riely G J	2011	J Clin Oncol2011，29，：	1
15	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis显示文摘	Alice T Shaw Beow Y Yeap Benjamin J Solomon Gregory J Riely Justin Gainor Jeffrey A Engelman Geoffrey I Shapiro Daniel B Costa Sai-Hong I Ou Mohit Butaney Ravi Salgia Robert G Maki Marileila Varella-Garcia Robert C Doebele Yung-Jue Bang Kimary Kulig Pauli	2011	Lancet Oncology2011，，11：	1
16	Erlotinib at a dose of 25 mg daily for non small cell lung cancers with EGFR mutations显示文摘	Yeo W L Riely G J Yeap B Y	2010	J ThoracOncol2010，5，7：	1
17	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis显示文摘	Alice T Shaw Beow Y Yeap Benjamin J Solomon Gregory J Riely Justin Gainor Jeffrey A Engelman Geoffrey I Shapiro Daniel B Costa Sai-Hong I Ou Mohit Butaney Ravi Salgia Robert G Maki Marileila Varella-Garcia Robert C Doebele Yung-Jue Bang Kimary Kulig Pauli	2011	Lancet Oncology2011，，11：	1
18	Clinical course of patients with non small cell lung cancer and epidermal growth factor receptor Exonl9 and Exon 21 mutations treatedwith gefitinib or erlotinib 显示文摘	Riely G J Pao W Pham D	2006	Clin Cancer Res2006，12，3：	1
19	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib显示文摘	Riely G J Pao W Pham D	2006	Clin Cancer Res2006，12，31：	1
20	hnpact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognos- tic subgroups and implications for further revision of staging based on analysis of 514 stage I cases 显示文摘	Yoshizawa A Motoi N Riely G J	2011	Mod Pathol2011，24，5：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示